Global Nucleic Acid Amplification Testing Market Size study, by Type (Polymerase Chain Reaction (PCR) Tests, Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, Ligase Chain Reaction (LCR) Tests), by Application (Infectious Disease Testing, On

Global Nucleic Acid Amplification Testing Market Size study, by Type (Polymerase Chain Reaction (PCR) Tests, Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, Ligase Chain Reaction (LCR) Tests), by Application (Infectious Disease Testing, Oncology Testing, Genetic & Mitochondrial Disease Testing, Others), by End-use (Hospitals, Central And Reference Laboratories, Others) and Regional Forecasts 2022-2032

The Global Nucleic Acid Amplification Testing Market is valued at approximately USD 8.19 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.2% over the forecast period 2024-2032. Nucleic Acid Amplification Testing (NAAT) is a molecular technique used to detect and amplify specific nucleic acid sequences, such as DNA or RNA, from pathogens or genetic material. This method includes PCR (Polymerase Chain Reaction), RT-PCR (Reverse Transcription PCR), and LAMP (Loop-Mediated Isothermal Amplification). NAAT is highly sensitive and specific, making it valuable for diagnosing infectious diseases like COVID-19, tuberculosis, and HIV. It is also used in genetic testing, cancer detection, and forensic science. NAAT enables early and accurate detection of diseases, guiding appropriate treatment and management strategies.

The market's growth is fueled by a surge in demand for advanced rapid diagnostics and rising R&D investments in developing novel biotechnological diagnostic techniques. The high global prevalence of infectious diseases and the need for highly efficient testing alternatives to successfully manage disease outbreaks have propelled the demand for various nucleic acid amplification testing technologies. COVID-19, in particular, has significantly increased the demand for rapid and accurate testing methods to detect the SARS-CoV-2 virus. Key market players have responded by developing new product offerings, such as isothermal nucleic acid amplification technology-based tests, to meet the high demand for rapid and point-of-care testing.

The major factors driving the NAAT market include the rising prevalence of infectious diseases, increasing demand for advanced diagnostic measures, and growing investment in developing new biotechnological diagnostic techniques. However, a lack of skilled professionals and the higher costs associated with these tests may restrain the market's growth. Nonetheless, the global increase in healthcare spending and continuous advancements in diagnostic technology provide significant growth opportunities for the NAAT market.

North America dominated the market in 2023, accounting for the largest revenue share due to the high prevalence of chronic diseases and the presence of an established research and healthcare infrastructure. The demand for nucleic acid amplification tests in the region is driven by the increasing focus on point-of-care diagnostic methods and extensive disease prevention measures. In contrast, the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, driven by its large population and rising focus on healthcare systems. The high incidence of emerging infectious diseases such as Japanese encephalitis, Hendra, and Nipah virus infections can strengthen the market prospects for nucleic acid amplification testing in the region.

Major market players included in this report are:

F. Hoffmann-La Roche Ltd

Becton, Dickinson and Company

Danaher Corporation

Abbott Laboratories

Illumina, Inc.

Siemens Healthineers

bioMérieux SA

Novartis AG

Bio-Rad Laboratories, Inc.

Seegene Inc.

The detailed segments and sub-segment of the market are explained below:

By Type:
• Polymerase Chain Reaction (PCR) Tests
• Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
• Ligase Chain Reaction (LCR) Tests

By Application:
• Infectious Disease Testing
• Oncology Testing
• Genetic & Mitochondrial Disease Testing
• Others

By End-use:
• Hospitals
• Central And Reference Laboratories
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico
• RoLA

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.